CA2798518A1 - Pegylated c-peptide - Google Patents
Pegylated c-peptide Download PDFInfo
- Publication number
- CA2798518A1 CA2798518A1 CA2798518A CA2798518A CA2798518A1 CA 2798518 A1 CA2798518 A1 CA 2798518A1 CA 2798518 A CA2798518 A CA 2798518A CA 2798518 A CA2798518 A CA 2798518A CA 2798518 A1 CA2798518 A1 CA 2798518A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- pegylated
- patient
- insulin
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims abstract 104
- 108010075254 C-Peptide Proteins 0.000 claims abstract 99
- 238000000034 method Methods 0.000 claims abstract 19
- 230000004071 biological effect Effects 0.000 claims abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 50
- 102000004877 Insulin Human genes 0.000 claims 25
- 108090001061 Insulin Proteins 0.000 claims 25
- 229940125396 insulin Drugs 0.000 claims 25
- 238000011287 therapeutic dose Methods 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000033808 peripheral neuropathy Diseases 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 230000007774 longterm Effects 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 230000007830 nerve conduction Effects 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- 208000013016 Hypoglycemia Diseases 0.000 claims 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 238000002983 circular dichroism Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34529310P | 2010-05-17 | 2010-05-17 | |
| US61/345,293 | 2010-05-17 | ||
| US201161448402P | 2011-03-02 | 2011-03-02 | |
| US61/448,402 | 2011-03-02 | ||
| PCT/US2011/036858 WO2011146518A2 (en) | 2010-05-17 | 2011-05-17 | Pegylated c-peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2798518A1 true CA2798518A1 (en) | 2011-11-24 |
Family
ID=44992295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2798518A Abandoned CA2798518A1 (en) | 2010-05-17 | 2011-05-17 | Pegylated c-peptide |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8927488B2 (enExample) |
| EP (1) | EP2571896A4 (enExample) |
| JP (1) | JP2013533217A (enExample) |
| KR (1) | KR20130115086A (enExample) |
| CN (1) | CN103119055A (enExample) |
| CA (1) | CA2798518A1 (enExample) |
| MX (1) | MX2012013375A (enExample) |
| NZ (1) | NZ603399A (enExample) |
| WO (1) | WO2011146518A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| EP4450523A3 (en) * | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US8927488B2 (en) | 2010-05-17 | 2015-01-06 | Cebix, Inc. | Pegylated C-peptide |
| EP2755675B1 (en) * | 2011-09-12 | 2018-06-06 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| CN104220086A (zh) * | 2011-11-17 | 2014-12-17 | 塞比克斯股份公司 | Peg化的c-肽 |
| US20130288973A1 (en) * | 2011-12-14 | 2013-10-31 | Edmund Burke | Decellularized small particle tissue |
| US9988433B2 (en) * | 2013-03-14 | 2018-06-05 | Mosaic Biosciences, Inc. | Covalent modification of biological macromolecules |
| WO2013116791A1 (en) | 2012-02-02 | 2013-08-08 | Mosaic Biosciences, Inc. | Biomaterials for delivery of blood extracts and methods of using same |
| US20150087586A1 (en) * | 2012-03-29 | 2015-03-26 | Cebix, Inc. | Pegylated c-peptide |
| US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
| EP3021834A1 (en) * | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| AU2014328458B2 (en) * | 2013-09-24 | 2020-03-12 | Allergan Pharmaceuticals International Limited | Method of extracting protein |
| KR20170116109A (ko) | 2015-02-09 | 2017-10-18 | 모자이크 바이오사이언스 인코포레이션 | 분해성 티올-엔 중합체 및 그의 제조 방법 |
| JP6937984B2 (ja) * | 2015-03-03 | 2021-09-22 | ナンシャ・バイオロジックス・（ホンコン）・リミテッドＮａｎｓｈａ Ｂｉｏｌｏｇｉｃｓ （Ｈｏｎｇ Ｋｏｎｇ） Ｌｉｍｉｔｅｄ | ペグ化ｉｌ−１１の組成物および方法 |
| US10627415B2 (en) | 2015-03-12 | 2020-04-21 | Board Of Trustees Of Michigan State University | Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease |
| CN114805540A (zh) * | 2015-09-18 | 2022-07-29 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
| CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
| ES2989204T3 (es) | 2017-06-16 | 2024-11-25 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| JP7058857B2 (ja) * | 2017-08-30 | 2022-04-25 | クラシエホームプロダクツ株式会社 | 毛髪タンパク質の水との相互作用測定方法 |
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| US12226546B2 (en) * | 2017-09-28 | 2025-02-18 | The Regents Of The University Of California | Polyion complex polypeptide hydrogels and uses thereof |
| WO2019066609A1 (ko) | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법 |
| HRP20240475T8 (hr) * | 2017-12-01 | 2024-08-02 | Csl Behring Llc | A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica |
| CA3084013A1 (en) | 2017-12-01 | 2019-06-06 | StemRIM Inc. | Ectodermal mesenchymal stem cells and method for producing same |
| AU2019268410B2 (en) * | 2018-05-16 | 2025-01-02 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
| EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| CN113423466B (zh) * | 2018-10-25 | 2025-04-25 | 国立大学法人大阪大学 | 软骨病症的治疗剂 |
| MX2021005757A (es) | 2018-11-15 | 2021-08-11 | Quantum Si Inc | Metodos y composiciones para la secuenciacion de proteinas. |
| US20220177704A1 (en) * | 2019-03-27 | 2022-06-09 | The Regents Of Theuniversity Of California | Mixtures of synthetic copolypeptide hydrogels |
| KR102836637B1 (ko) * | 2019-03-29 | 2025-07-21 | 니치유 가부시키가이샤 | 분기형 분해성 폴리에틸렌 글리콜 유도체 |
| US12390534B2 (en) | 2019-03-29 | 2025-08-19 | Nof Corporation | Branched degradable polyethylene glycol binder |
| CN111939244B (zh) * | 2019-05-14 | 2024-08-06 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| KR102456958B1 (ko) | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| JP7750489B2 (ja) * | 2020-04-20 | 2025-10-07 | 塩野義製薬株式会社 | Ｈｍｇｂ１部分ペプチドを含有する製剤 |
| US12090206B2 (en) | 2020-04-23 | 2024-09-17 | The Regents Of The University Of California | Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels |
| US12065466B2 (en) * | 2020-05-20 | 2024-08-20 | Quantum-Si Incorporated | Methods and compositions for protein sequencing |
| CN114137094A (zh) * | 2020-09-03 | 2022-03-04 | 北京渼颜空间生物医药有限公司 | 一种聚左旋乳酸中有关物质的检测方法 |
| US20220401525A1 (en) * | 2021-06-16 | 2022-12-22 | Biocell Technology, Llc | Use of collagen compositions for increasing telomere length |
| CN116554267A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇修饰的激肽或其变体和药物应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1176158A (en) * | 1981-08-27 | 1984-10-16 | Ronald E. Chance | Pharmaceutical formulations comprising human insulin and human c-peptide |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| FR2686759B1 (fr) | 1992-01-29 | 1994-04-22 | Sgs Thomson Microelectronics | Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie . |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| EP1609478A1 (en) * | 1999-01-14 | 2005-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptide formulations |
| US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| JP4861586B2 (ja) | 1999-12-22 | 2012-01-25 | ネクター セラピューティックス | 水溶性ポリマーの立体的に妨害される誘導体 |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| DE10055742B4 (de) | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7265186B2 (en) | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| SI1430082T1 (sl) | 2001-09-07 | 2010-02-26 | Biocon Ltd | Postopki za sintetiziranje konjugatov inzulinski polipeptid-oligomer in konjugati proinzulinski polipeptid-oligomer in postopki za njihovo sintetiziranje |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| KR100948532B1 (ko) * | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
| KR20070072924A (ko) * | 2001-11-20 | 2007-07-06 | 파마시아 코포레이션 | 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트 |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| AP2005003246A0 (en) | 2002-09-09 | 2005-03-31 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| WO2005002597A1 (en) | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| US7744861B2 (en) | 2003-09-17 | 2010-06-29 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| AU2005238490B2 (en) * | 2004-04-22 | 2010-11-18 | Tobira Therapeutics, Inc. | Improved modulators of coagulation factors |
| US9085659B2 (en) | 2004-05-03 | 2015-07-21 | Nektar Therapeutics | Polymer derivatives comprising an imide branching point |
| WO2005108463A2 (en) | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
| GB0412174D0 (en) * | 2004-06-01 | 2004-06-30 | Creative Peptides Sweden Ab | Degradation-resistant analogues of pro-insulin c-peptide |
| EP1850878A2 (en) * | 2005-02-10 | 2007-11-07 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| WO2006097521A1 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| EP1926768B1 (en) | 2005-07-18 | 2011-09-14 | Nektar Therapeutics | Branched functionalized polymers using branched polyol cores |
| GB0601950D0 (en) | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
| JP4261531B2 (ja) | 2005-09-06 | 2009-04-30 | 株式会社Ｎｒｌファーマ | ラクトフェリン複合体及びその製造方法 |
| EP2043692B1 (en) * | 2006-07-25 | 2016-05-18 | Lipoxen Technologies Limited | Polysaccharide derivatives of erythropoietin |
| WO2008015099A2 (en) * | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| RU2007137048A (ru) * | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете |
| US20110182946A1 (en) | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
| EP2350118B1 (en) * | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033204A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| WO2011081915A2 (en) | 2009-12-15 | 2011-07-07 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| US8927488B2 (en) | 2010-05-17 | 2015-01-06 | Cebix, Inc. | Pegylated C-peptide |
-
2011
- 2011-05-17 US US13/109,522 patent/US8927488B2/en not_active Expired - Fee Related
- 2011-05-17 JP JP2013511302A patent/JP2013533217A/ja active Pending
- 2011-05-17 CA CA2798518A patent/CA2798518A1/en not_active Abandoned
- 2011-05-17 WO PCT/US2011/036858 patent/WO2011146518A2/en not_active Ceased
- 2011-05-17 NZ NZ603399A patent/NZ603399A/en not_active IP Right Cessation
- 2011-05-17 CN CN2011800350917A patent/CN103119055A/zh active Pending
- 2011-05-17 KR KR1020127031723A patent/KR20130115086A/ko not_active Withdrawn
- 2011-05-17 MX MX2012013375A patent/MX2012013375A/es not_active Application Discontinuation
- 2011-05-17 EP EP11784109.8A patent/EP2571896A4/en not_active Withdrawn
-
2012
- 2012-05-04 US US13/463,887 patent/US8691755B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2571896A4 (en) | 2014-01-08 |
| CN103119055A (zh) | 2013-05-22 |
| WO2011146518A9 (en) | 2012-04-19 |
| EP2571896A2 (en) | 2013-03-27 |
| US8691755B2 (en) | 2014-04-08 |
| MX2012013375A (es) | 2013-04-11 |
| KR20130115086A (ko) | 2013-10-21 |
| JP2013533217A (ja) | 2013-08-22 |
| US8927488B2 (en) | 2015-01-06 |
| US20120178676A1 (en) | 2012-07-12 |
| WO2011146518A2 (en) | 2011-11-24 |
| WO2011146518A3 (en) | 2012-03-08 |
| NZ603399A (en) | 2014-09-26 |
| US20120220542A1 (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2798518A1 (en) | Pegylated c-peptide | |
| KR102665710B1 (ko) | Glp-1 조성물 및 그 용도 | |
| US11318191B2 (en) | GLP-1 compositions and uses thereof | |
| JP2014526441A5 (enExample) | ||
| Camillieri et al. | Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect | |
| AU2014346051B2 (en) | Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| CA2440744C (en) | Il-12 expression controlling agent | |
| KR20250024094A (ko) | 안정한 세마글루티드 조성물 및 이의 용도 | |
| US20220153800A1 (en) | Gm-csf mimetics and methods of making and using same | |
| KR20180096733A (ko) | 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제 | |
| US7297676B2 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| CA2709027A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| WO2024056028A1 (en) | Analgesic polypeptide | |
| JP5189985B2 (ja) | コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法 | |
| KR101560339B1 (ko) | 의약 조성물 또는 조합제 | |
| RU2010152972A (ru) | Способ лечения острого нарушения мозгового и спинального кровообращения ишемического и геморрагического характера | |
| CN114588164B (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| US20210024928A1 (en) | C/ebp alpha sarna compositions and methods of use | |
| Zhang et al. | Novel XTENylated AWRK6 analog with hypoglycemic activity, and anti-HSV-2 potential in combination with double shRNA | |
| CA2470235A1 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| CN117180266B (zh) | 鼠尾草酚和/或迷迭香酚的药物新用途 | |
| EP4667566A1 (en) | Arginine deiminase mutant, covalent dimer and conjugate and use thereof | |
| US12486320B1 (en) | Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160519 |